152 results about "Hematological sample" patented technology

The invention relates to a blood rheological parameter online monitoring and thrombus risk assessment method, which comprises the following steps: introducing a blood sample into a microfluidic channel with a periodic geometric mutation structure, applying unsteady shear disturbance through a piezoelectric oscillation device, inducing blood to enter a non-equilibrium rheological state, and exciting a microcosmic coagulation tendency; the red blood cell aggregation behavior, the cell layer slippage phenomenon and the plasma shearing stability are recognized through the photo-thermal interference technology, and the rheological structure layer differentiation characteristics in blood are obtained; the blood subjected to shear disturbance is guided to a micro-channel high-pressure area provided with a flow-limiting threshold structure, and pressure mutation and microcoacervation nucleation generation behaviors induced by local stress disturbance are detected through a nanoscale piezoresistive sensor so as to identify sub-phase change response characteristics of the blood; and constructing a rheological instability index system on the basis of physical response signals obtained by shear disturbance, slippage and variable response, and when linkage abnormity of any two indexes is detected, judging that a high-risk event of thrombosis occurs and outputting a risk prompt signal.

The invention discloses a direct counting method and device for detecting the number of fluorescence-labeled rare abnormal cells in a blood sample. Aiming at the problem that direct counting of low-abundance cells is difficult to realize in a conventional blood container by a traditional detection means, the method realizes rapid and direct counting of rare abnormal cells by performing narrow-band filtering, efficient collection and high signal-to-noise ratio detection on a fluorescence signal emitted by a static blood sample. The device comprises a lighting source module, an exciting light and emitted light narrow-band filtering module, a light beam collimation and beam expansion module, a sample bearing module, an emitted light collection and detection module and a data processing and counting module. Accurate counting of the extremely-low-abundance fluorescence labeling abnormal cells can be completed in a conventional transparent container without flow sorting or complex treatment of a blood sample, and the method has the advantages of being easy and convenient to operate, high in detection speed, suitable for clinical screening and the like.

The application relates to the technical field of blood drug concentration detection, and discloses a blood drug concentration analysis method based on mass spectrometric detection, which comprises the following steps: adopting microfluidic technology in combination with solid-phase extraction to pretreat a blood sample to obtain a concentrated solution, so as to remove interfering components and concentrate target drug molecules; according to the physicochemical properties of the target drug molecules, the concentrated solution is selected to flow through a biosensor or is directly introduced into a chromatographic unit, and the target drug molecules in the liquid phase are converted into gas-phase ions when flowing through the biosensor; chromatography-mass spectrometry is adopted to detect the gas-phase ions or the concentrated solution, so as to obtain mass spectrum data; a machine learning model is used to analyze the spectrum data, to identify the drug types and calculate the concentration of the target drug molecules, and to generate an analysis report. The method is suitable for target drugs with different physicochemical properties, simplifies the detection process, and improves the applicability and accuracy of detection.

The present application relates to the technical field of tumor cell detection chip, in particular to a kind of based on inertial microfluidic tumor cell mechanical property detection device and method, the present application adopts sine microfluid channel inertial focusing cell, and the mechanical property detection of cell multiple deformation in channel is carried out by high-speed camera.The cell suspended in PBS is subjected to the combined action of inertial force and dean force in sine microfluid channel, and the single-column focusing of cell can be realized in a wide flow rate range, and the recognition accuracy of optical detection is improved.Cell is subjected to shear force, tensile force and wall collision in microfluid channel and generates three deformations, and different types and sizes of force make cell produce different degrees and shapes of deformation.The size, roundness, deformation and circumscribed rectangle size of cell in different deformations are extracted, and the classification model of species is trained using machine learning method, to identify cell species.The present application is suitable for the detection of various cells in blood samples and biological particles in other biological samples.

A microfluidic, chip-based assay device has been developed for measuring physical properties of an analyte (particularly, whole blood or whole blood derivatives). The technologies can be applied to measure clotting times of whole blood or blood derivatives, determine the effects of anticoagulant drugs on the kinetics of clotting / coagulation, as well as evaluate the effect of anticoagulant reversal agents. These technologies can additionally be used to optimize the dosage of anticoagulation drugs and / or their reversal agents. The assay is independent of the presence of anticoagulant; clotting is activated by exposure of the blood sample in the device to a glass (or other negatively charged material such as oxidized silicon) surface, which activates the intrinsic pathway and can be further hastened by the application of shear flow across the activating materials surface. The absence of chemical activating agents and highly controlled and reproducible micro-environment yields a point of care universal clotting assay.

The invention relates to the technical field of biological detection, and discloses a sample diluent and application thereof and a kit, pure water is taken as a solvent, and the sample diluent at least comprises 15-80 g / L of soluble sodium salt, 0.05-0.5 g / L of soluble potassium salt, 8-15 g / L of amino acid, 0.2-1 g / L of goat serum albumin, 0.2-1 g / L of surfactant, 0.5-2 g / L of trehalose and 0.5-2 mL / L of Proclin-300 according to concentration, the sample diluent provided by the invention can weaken non-specific binding of impurities in a blood sample and a target analyte, so that the accuracy of a final detection result is improved.

The present disclosure presents glucose sensing methods and systems. One such system comprises an electrospun-nanofibrous-membrane (ENFM)-based amperometric glucose sensor integrated on a silicon chip, in which the glucose sensor has a working electrode, a reference electrode, and a counter electrode, wherein the working electrode comprises an ENFM-based sensing electrode. The system further comprises a potentiostat circuit integrated on the silicon chip such that the potentiostat circuit comprises a voltage control unit to control a voltage difference between the working electrode and the reference electrode and a transimpedance amplifier to measure a current flow between the working electrode and the counter electrode, in which a strength of the current flow corresponds to an amount of glucose present in a sample of blood on the glucose sensor.

A method for determining whether a subject is at risk for having a progressing or high-grade pre-invasive lesion, nodule or small mass, or having a solid malignant tumour is described the method comprising: (i) determining a ratio of activated and / or exhausted T cells:naive and / or resting T cells in a sample of blood obtained from the subject, wherein the determining comprises analysing T cells using cytometry to detect the presence or absence of a panel of biomarkers comprising Ki67 and CD39, or (ii) determining a ratio of activated and / or exhausted T cells:T cells which are not activated and / or exhausted T cells in a sample of blood obtained from the subject, wherein the determining comprises analysing T cells using cytometry to detect the presence or absence of a panel of biomarkers comprising Ki67 and CD39, (iii) determining a proportion of activated and / or exhausted T cells as a percentage of T cells in a sample of blood obtained from the subject, wherein the determining comprises analysing T cells using cytometry to detect the presence of a panel of biomarkers comprising Ki67 and CD39, and / or (iv) determining a proportion of activated and / or exhausted T cells as a percentage of T cells in a sample of blood obtained from the subject, wherein the T cells are CD4 T cells, and wherein the determining comprises analysing T cells using cytometry to detect the presence of a panel of biomarkers comprising FoxP3.

The present invention provides a novel means usable for predicting a therapeutic effect of a combination therapy of an IL-6 inhibitor and a chemotherapy in a pancreatic cancer patient, said means being characterized by use of blood CD8-positive effector memory T cells as a biomarker. Specifically, in order to predict a therapeutic effect of a combination therapy of an IL-6 inhibitor and a chemotherapy in a pancreatic cancer patient, (i) the level of CD8-positive effector memory T cells that are contained in a blood sample which is collected from the pancreatic cancer patient is measured and (ii) when the level of the CD8-positive effector memory T cells is high, it is determined that the therapeutic effect yielded by the combination therapy is high.

The invention provides a data processing device for pulmonary tuberculosis disease risk assessment and application thereof. The data processing device provided by the invention comprises a memory, a processor and a computer program stored on the memory, and the processor executes the computer program to realize the following steps: receiving gene expression quantity data in a blood sample of a subject, performing pulmonary tuberculosis disease risk grouping on the subjects according to the gene expression quantity data; the gene at least comprises an aspartate beta-hydroxylase structural domain 2 gene (ASPHD2). The data processing device provided by the invention can be used for evaluating or assisting in evaluating the pulmonary tuberculosis disease risk of the subject, improves the accuracy of risk evaluation, and has a relatively high clinical application value.

The invention discloses application of C1INH in preparation of a product for prediction or auxiliary diagnosis of preeclampsia and the product, belongs to the technical field of biological medicines, and aims to detect the content of C1INH in a blood sample on a protein level by taking the blood sample of a subject as a detection object. According to the invention, C1INH molecules in blood are taken as a detection index, prediction and auxiliary diagnosis of preeclampsia of pregnant women can be realized, high sensitivity and specificity are realized, rapid detection can be realized, and a new way is provided for early screening and diagnosis of preeclampsia in the prior art.

The invention provides a full-automatic detection device and method for the concentration of free drugs in blood. The full-automatic detection method adopts a full-automatic detection device and comprises the following steps: (1) loading a blood sample to a protein purification chromatographic column by adopting a pump 1 and an automatic sampler, removing protein components in the blood sample, and retaining free drug components on the protein purification chromatographic column; (2) enabling free drug components in the protein purification chromatographic column to flow into a trapping column and enriching the free drug components in the trapping column; and (3) enabling the free drug components in the trapping column to flow into an analytical column, separating, and detecting in a triple quadrupole mass spectrometer. Through the specific full-automatic detection device, the problems that total drug concentration monitoring cannot meet clinical treatment requirements, and the free drug pretreatment process is complex, long in time and high in cost are solved, clinical individualized drug administration can be assisted, the drug curative effect is improved, and the toxic and side effects of drugs are reduced.

The invention discloses a post-AMI heart failure oxidized lipid screening method based on solid phase extraction, LC-MS / MS and AI. The method comprises the steps of blood sample pretreatment, solid phase extraction and purification, LC-MS / MS detection and AI model screening. According to the method, high-sensitivity qualitative and quantitative detection of oxidized lipid is realized through optimized LC-MS / MS parameters, and key oxidized lipid molecules and risk levels of heart failure after AMI emergency treatment blood supply reconstruction can be quickly and accurately screened in combination with a trained random forest AI model; the kit solves the problems that in the prior art, trace oxidized lipid detection sensitivity is low, specificity is poor, and heart failure risk screening lags, has the advantages of being high in detection efficiency, good in accuracy and high in practicability, can provide a scientific basis for early warning and intervention of clinical heart failure after AMI, and has high clinical application value.

For analyzing a sample containing particles of at least two categories, such as a sample containing blood cells, a particle counter subject to a detection limit is coupled with an analyzer capable of discerning particle number ratios, such as a visual analyzer, and a processor. A first category of particles can be present beyond detection range limits while a second category of particles is present within respective detection range limits. The concentration of the second category of particles is determined by the particle counter. A ratio of counts of the first category to the second category is determined on the analyzer. The concentration of particles in the first category is calculated on the processor based on the ratio and the count or concentration of particles in the second category.

The invention relates to the technical field of biomedical detection, and particularly discloses a biomarker for diagnosing treatment-related liver injury of a primary liver cancer patient in a combined treatment process based on an immune checkpoint inhibitor and application of the biomarker. The biomarker is a collagen XII type alpha 1 chain (COL12A1) and a voltage dependent calcium channel alpha 2 / delta 1 subunit (CACNA2D1). By detecting the expression level of COL12A1 and / or CACNA2D1 protein in a blood sample of a subject and comparing the expression level with a normal level, specific diagnosis for treating related liver injury can be realized. ROC curve analysis verifies that the diagnosis AUC values of the two markers on liver injury are both greater than 0.85, and the two markers have excellent diagnosis efficiency. The invention also relates to a kit for detecting the biomarker.

Provided herein are methods for detecting the presence of microfilariae in a blood sample. Generally, the methods include pouring a blood sample comprising erythrocytes onto a porous filter, wherein the porous filter captures microfilaria on a surface of the porous filter; drawing the erythrocytes through the porous filter, leaving a remaining sample on the surface of the porous filter; fluorescently labeling the remaining sample to form a labeled sample; washing the labeled sample; imaging the surface of the porous filter using an imaging system; and detecting the presence of microfilariae based on fluorescence in the images.

The invention relates to the technical field of medical data processing, and discloses a blood cell analyzer for tumor cell recognition and a method thereof, and the method comprises the following steps: adding epithelial-mesenchymal transition phenotype specific fluorescent dye for double staining; focusing the dyed sample into a single-row liquid flow, and enabling the single-row liquid flow to sequentially pass through a detection area; synchronously collecting a multispectral photoacoustic signal, a laser scattering signal and an impedance signal of the cells in the liquid flow; carrying out fusion processing on the collected multi-dimensional signals, and extracting morphological characteristics, biochemical characteristics and acoustic characteristics of the cells; the extracted features are input into a pre-trained improved convolutional neural network model, a tumor cell recognition result and type judgment are output, and the types comprise an epithelial type, a mesenchymal type or a mixed type; and outputting a detection report. According to the invention, automatic, high-precision and rapid identification of tumor cells in a blood sample is realized, the detection cost is reduced, and a reliable basis is provided for early screening and diagnosis of tumors.

The application relates to the technical field of biological detection, and discloses a sample diluent, application and kit thereof, wherein the solvent is pure water and at least includes 15-80 g / L of soluble sodium salt, 0.05-0.5 g / L of soluble potassium salt, 8-15 g / L of amino acid, 0.2-1 g / L of goat serum albumin, 0.2-1 g / L of surfactant, 0.5-2 g / L of trehalose and 0.5-2 mL / L of Proclin-300; the amino acid is an alkaline amino acid; and the sample diluent provided by the application can weaken the non-specific combination of impurities and target analytes in a blood sample, thereby improving the accuracy of a final detection result.

The objective is to provide a simple and indirect method for estimating the rate of senescent immune cells (the ratio of immune cells with high SAβgal expression levels among T cells whose surface marker is CD8-positive) using a small amount of blood sample. [Solution] This method estimates the rate of senescent immune cells using the relative expression levels of one or more selected from Granzyme K, α-Klotho, GDF15, PAI-1 (SERPIN1), and ferritin in the blood.

The invention relates to a cell image analyzer, a sample analysis system and a cell image analysis method. The cell image analyzer comprises: an imaging device for shooting a cell image; the bearing device is used for bearing the blood smear on which the blood film is applied; the control device is used for controlling the blood smear and the imaging device to move relative to each other, so that a plurality of shooting points in a target area of the blood film are respectively positioned in a visual field of the imaging device, and controlling the imaging device to shoot images of the shooting points in the visual field of the imaging device so as to obtain target cell images of the plurality of shooting points in the target area; the image analysis device is used for identifying platelets in the multiple target cell images and acquiring actual platelet distribution information of the blood membrane based on the platelets identified in the multiple target cell images and the shooting positions of the multiple target cell images in the smearing direction; and based on the actual platelet distribution information, acquiring platelet count and / or judging whether the to-be-detected blood sample is a platelet aggregation sample or not.

The invention relates to the technical field of image processing, in particular to a hemolysis sample detection method based on deep learning, which comprises the following steps: constructing a deep learning model special for hemolysis sample detection, which comprises a deep sensing branch and a brightness analysis branch; carrying out standardization processing on the collected blood sample image, wherein the standardization processing comprises size zooming, normalization and normalization operation; inputting the standardized image into a deep learning model, respectively processing the image through a deep sensing branch and a brightness analysis branch to obtain a high-level semantic information tensor and a brightness feature information tensor, splicing the high-level semantic information tensor and the brightness feature information tensor into a one-dimensional tensor, inputting the one-dimensional tensor into a full connection layer, mapping the tensor into three-classification probability distribution, and completing final sample classification; and carrying out model training on the deep learning model. The problems that an existing hemolysis sample detection method is low in efficiency, high in subjectivity, inconsistent in result, greatly affected by illumination and the like are effectively solved.

The invention belongs to the technical field of biomedical detection, and discloses a biomarker for predicting or diagnosing diabetic peripheral neuropathy and application of the biomarker, and the biomarker comprises GREM2 and HPD. The biomarker disclosed by the invention is high in sensitivity, strong in specificity, capable of accurately identifying DPN and reliable in detection result, the AUC value of combined diagnosis of two differential proteins reaches 0.86, and the biomarker is remarkably superior to an existing clinical marker. When the biomarker is combined with clinical markers Age, BMI, T2DM daughter and HbA1c for use, the AUC value of the biomarker can reach 0.95. When the biomarker is applied, only a small number of blood samples of a patient are needed, the detection method is simple, convenient and rapid, the professional requirement is not high, and the biomarker is suitable for clinical popularization.

Disclosed is a method of diagnosing multiple sclerosis (MS), wherein a blood sample from a patient is incubated with a DNA-replication associated (REP) protein. The present invention relates to a DNA-replication-associated (Rep) protein for use in the diagnosis of multiple sclerosis (MS), wherein (a) Aan increased amount of Rep protein or fragments thereof in the sample as compared to an amount in a control sample; or an increased amount of anti-Rep protein antibodies with antigen in a sample from a subject as compared to an amount in a control sample correlates with a diagnosis of MS, wherein the Rep protein is MSBI1 Rep or MSBI2 Rep.

The invention provides a hemolysis index quality control product as well as a preparation method and application thereof. The hemolysis index quality control product provided by the invention comprises serum, a preservative and a hemolysis component, the serum, the preservative and the hemolysis component are mixed in advance according to different preset proportions to obtain quality control products with different hemolysis indexes; the hemolysis component is a blood sample with damaged red blood cells or a hemoglobin standard substance; the preservative is 0.05% of sodium azide. The hemolysis index quality control product provided by the invention can be used for monitoring the reaction and detection capability of a clinical laboratory inspection instrument on a hemolysis sample, and can also be used for assisting biochemical detection, analysis and judgment.

A computer-implemented method for determining states in vivo and in vitro by analyzing blood parameters, including obtaining blood parameters of a blood sample by a hematology analyzer, the blood parameters including quantitative and qualitative measurement variables, and the measurement variables include properties of individual cells, and the individual cells comprise blood cells. The computer-implemented method further includes creating a scatterplot having at least two axes, and each axis of the scatterplot comprises a different measurement variable; and determining an in-vivo and / or in-vitro and / or post-mortem state by a deep learning model and / or a machine learning model. The input variable for the deep learning model includes a scatterplot, and the input variable for the machine learning model includes 1D vector. The 1D vector is created by vectorizing the scatterplot; and automatically generating a report including the result regarding the determination of the state.

Viscoelastic coagulation monitoring systems having two glass discs mounted on flexible plastic arms for receiving a sample of blood therebetween, and an analyzer configured to measure a coagulation response of the sample of blood to determine whether the sample of blood indicates a hypercoagulable state in a HS patient are provided. The system may cause movement of a first glass disc relative to a second glass disc at a sufficient speed to cause coagulation of the sample of blood, and the analyzer may measure various parameters of the coagulation response including, e.g., Clotting Time (CT), Clot Formation Time (CFT), Alpha Angle (a-angle), Maximum Clot Firmness (MCF), Amplitude at 10 and 20 minutes (A10, A20, respectively), Lysis Index at 30 and 45 minutes (LI30 and LI45, respectively), indicative of a hypercoagulable state in a HS patient.

The application discloses a nucleic acid absolute quantification method based on nucleic acid constant temperature amplification, which comprises the following specific steps: step one, sample pretreatment, blood samples and saliva samples are pretreated respectively; step two, reaction system configuration and assembly; step three, digital micro-reaction unit preparation and amplification; and step four, multiple signal analysis and absolute quantification. In the application, multiple primer design and a double-probe system are adopted, so that the mutation detection rate is improved, and the detection limit can be reduced to 0.1% variation through Cas12a-sgRNA auxiliary verification. The double-emulsification technology of the micro-fluidic chip is adopted, so that the droplet diameter variation coefficient is controlled within 5%, and the clogged micropore rate is reduced by real-time analysis of the micropore array image through the ImageJ software, automatic marking and exclusion of abnormal units.

The invention provides methods of determining the neutrophil level in a sample by determining the level of CD16b, including the intracellular form of CD16b in a sample, such as a blood sample. The methods may further comprise the determination of lactate levels Also provided are associated diagnostic and therapeutic methods. Further provided are kits and devices for performing the methods, particularly lateral flow kits and devices.

The invention belongs to the technical field of biology, and particularly relates to a reagent for detecting pathogenic genes as well as a preparation method and application thereof. The invention finds that a biological sample is enriched through broad-spectrum captured protein, the captured protein is labeled with biotin, pathogenic microorganisms are separated from the biological sample through high-density streptavidin coated magnetic beads, the pathogenic microorganisms are split after pure culture, pathogenic genes are detected after nucleic acid is extracted, and the turnover time is shortened to 4 hours. The precise distribution of nucleic acid is realized through an annular array reaction cavity preloaded with 32 freeze-dried LAMP reagents in combination with centrifugal force driving. The single chip synchronously detects more than or equal to 30 major pathogen genes / drug-resistant genes, covers common bloodstream infection pathogens, and breaks through the existing POCT flux bottleneck. According to the present invention, with the kit, the blood matrix inhibition can be eliminated, the pathogen concentration can be rapidly increased (the detection threshold value can be reached after culture), the positive detection rate can be increased to the clinical requirement level (gt, 90%), and the pathogen detection limit in the blood sample can meet the clinical critical infection early diagnosis requirement of less than or equal to 10 CFU / mL;

The invention discloses a high-flux biological particle separation system based on a micro-fluidic chip. The high-flux biological particle separation system comprises a micro-fluidic BAW chip, a micro-fluidic cascade chip and a plurality of DLD separation units, wherein a separation outlet area in the microfluidic BAW chip is provided with an extracellular vesicle collection channel, and the radiation assembly comprises a first piezoelectric transducer and a second piezoelectric transducer which are respectively used for providing high-frequency bulk acoustic waves and low-frequency bulk acoustic waves; a liquid inlet channel of the microfluidic cascade chip is connected with an extracellular vesicle collection channel, and a fluid distribution area is provided with a plurality of parallel branch channels; and the DLD separation units are connected with the parallel branch channels in a one-to-one correspondence manner. Through reasonable configuration of the multi-stage separation structure, multi-target separation of biological particles with different sizes in a blood sample can be realized.